Munich, Germany: A new anti-cancer drug that inhibits a key cell signalling process involved in many different cancers has shown that it is capable of stopping the progression of cancer and shrinking tumours. Importantly, it has been able to do this in rare cancers that are less well-studied such as adenoid cystic carcinoma. Dr Christophe […]
December 2016
Advanced soft tissue sarcomas respond to a combination of a new and an existing anti-cancer drug
Munich, Germany: Researchers working to find effective treatments for soft tissue sarcomas have discovered that combining a new anti-cancer drug with an existing one kills cancer cells not only in the laboratory but also in the first two patients treated with it, leading to unusually long-lasting periods without the disease progressing. Soft tissue sarcomas – […]
‘Revolution in our understanding of cancer’ sees dramatic responses to targeted treatments in advanced cancers
Results from three ground-breaking studies show early benefit to patients Munich, Germany: The “revolution in the understanding of cancer at the molecular level” has led to dramatic responses in cancer patients to new therapies that are targeted precisely at their particular type of tumours, according to an expert. Dr Kapil Dhingra, a member of the […]
How highs and lows in testosterone levels ‘shock’ prostate cancer cells to death
Munich, Germany: A strategy of alternately flooding and starving the body of testosterone is producing good results in patients who have metastatic prostate cancer that is resistant to treatment by chemical or surgical castration, according to new findings. In a presentation at the 28th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Munich, […]
Promising results from new drug combination in patients with advanced solid tumours
Munich, Germany: An experimental drug called TAS-114, which has the potential to increase the anti-cancer effects of chemotherapy without increasing adverse side effects, has shown promising results in patients with hard-to-treat cancers in a phase I clinical trial. In a presentation at the 28th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Munich, […]